<DOC>
	<DOCNO>NCT00593047</DOCNO>
	<brief_summary>Thyroid hormone know reduce cholesterol level regulation number key enzyme involve synthesis , degradation , lipid transport . However , currently market thyroid agonist non-selective , use treatment hypercholesterolemia due extrahepatic consequence hyperthyroidism , especially heart , bone , muscle . To take advantage thyroid hormone effect lipid metabolism treatment hypercholesterolemia , necessary develop selective thyroid receptor agonist induce hyperthyroidism liver , euthyroid state preserve extrahepatic tissue . KB2115 thyroid agonist develop liver selective . The purpose study assess efficacy safety KB2115 add therapy low middle dos statin follow 12 week exposure compare placebo . The aim study ass efficacy ( LDL-cholesterol lower effect ) safety KB2115 dose 25 100 µg define clinically relevant dose dose range future study .</brief_summary>
	<brief_title>LDL-Cholesterol Lowering Effect KB2115 Add Statin</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Signed informed consent 2 . Males female age 18 75 year . Female patient must nonfertile . To consider nonfertile , female must fulfil follow : Nonnursing nonpregnant 12 month prior enrolment Not child bear potential ie , either document irreversible surgically sterile ( bilateral oophorectomy hysterectomy acceptable , tubal ligation ) postmenopausal . Postmenopausal define serum folliclestimulating hormone ( FSH ) level postmenopausal range combine amenorrhea 1 year woman 50 year age , amenorrhea 2 year 50 year age 3 . Patients hypercholesterolemia treat stable dos list lipid lower medication least 3 month prior randomization Atorvastatin 20 mg/day Simvastatin 40 mg/day 4 . LDLcholesterol &gt; 3.0 mmol/L ( Week 1 ) 5 . Subject able willing comply study requirement 6 . At randomization , diet instruct investigator last 4 week prior randomization willingness follow instruction throughout study 1 . Cholesterol lower agent define statin 2 . History somatic psychiatric disease/condition , may interfere objective study judge investigator 3 . Clinically significant illness clinically relevant trauma within 2 week administration investigational product judge investigator 4 . Chronic ( &gt; 3 month ) pain condition require daily medication pain killer 5 . Glycosylated haemoglobin ( HbA1c ) &gt; 7.0 % 6 . Diabetes require medication metformin 7 . Clinically abnormal physical finding laboratory value judge investigator abnormal rest ECG , eg , QTc interval &gt; 450 msec 8 . Body Mass Index ≥ 40 kg/m2 9 . Resent history ( &lt; 3 month ) stroke transient ischemic attack 10 . History seizure disorder , except febrile convulsion 11 . A current diagnosis cancer , unless remission 12 . Blood pressure ( BP ) &gt; 160/95 mm Hg 13 . History cardiac arrhythmia , intermittent supraventricular tachyarrhythmia atrial fibrillation 14 . Unstable angina pectoris , myocardial infarction coronary bypass graft surgery percutaneous coronary intervention &lt; 6 month randomization 15 . Congestive heart failure New York Heart Association Class &gt; 2 16 . Unstable severe angina pectoris peripheral artery disease 17 . Known thyroid disease thyroid biomarkers ( TSH , T3 , free T3 , T4 , free T4 ) outside reference range normal enrolment baseline 18 . Positive urine pregnancy test woman enrolment 19 . Use thyroid replacement therapy hormone replacement therapy ( include contraceptive pill ) last 3 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>hypercholesterolemia</keyword>
</DOC>